Related Experiment Video
Updated: Jun 8, 2026
Isolation and Flow Cytometric Assessment of Neuroimmune Interactions in a Mini-Stroke Murine Model
Published on: June 20, 2025
Microglial activation in stroke: therapeutic targets
Midori A Yenari1, Tiina M Kauppinen, Raymond A Swanson
1Department of Neurology, University of California San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA.
Abstract:
Microglial activation is an early response to brain ischemia and many other stressors. Microglia continuously monitor and respond to changes in brain homeostasis and to specific signaling molecules expressed or released by neighboring cells. These signaling molecules, including ATP, glutamate, cytokines, prostaglandins, zinc, reactive oxygen species, and HSP60, may induce microglial proliferation and migration to the sites of injury. They also induce a nonspecific innate immune response that may exacerbate acute ischemic injury. This innate immune response includes release of reactive oxygen species, cytokines, and proteases. Microglial activation requires hours to days to fully develop, and thus presents a target for therapeutic intervention with a much longer window of opportunity than acute neuroprotection. Effective agents are now available for blocking both microglial receptor activation and the microglia effector responses that drive the inflammatory response after stroke. Effective agents are also available for targeting the signal transduction mechanisms linking these events. However, the innate immune response can have beneficial as well deleterious effects on outcome after stoke, and a challenge will be to find ways to selectively suppress the deleterious effects of microglial activation after stroke without compromising neurovascular repair and remodeling.
Insights
Microglial activation, an early brain injury response, can be therapeutically targeted. Suppressing harmful inflammation while preserving beneficial repair is key for stroke recovery.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Microglia are key immune cells in the brain, constantly monitoring homeostasis.
- They activate in response to brain ischemia and other stressors via signaling molecules like ATP and cytokines.
- This activation initiates an innate immune response that can worsen ischemic injury.
Purpose of the Study:
- To explore microglial activation as a therapeutic target for brain ischemia.
- To investigate the dual role of the innate immune response in stroke outcome.
- To identify strategies for selectively modulating microglial responses.
Main Methods:
- Review of signaling molecules inducing microglial proliferation and migration.
- Analysis of the time course of microglial activation.
- Examination of therapeutic agents targeting microglial pathways.
Main Results:
- Microglial activation is an early event in brain ischemia, occurring over hours to days.
- Signaling molecules like ATP, glutamate, and cytokines drive microglial proliferation and inflammation.
- Therapeutic agents exist to block microglial activation and downstream inflammatory responses.
Conclusions:
- Microglial activation presents a viable therapeutic target with a broad intervention window.
- The innate immune response by microglia has both detrimental and beneficial effects on stroke outcomes.
- Future strategies must selectively inhibit harmful microglial effects without impeding neurovascular repair.
